ImportRefusal LogoImportRefusal

GENFAR SANOFI

⚠️ High Risk

FEI: 3013021544 • Bogata • COLOMBIA

FEI

FEI Number

3013021544

📍

Location

Bogata

🇨🇴

Country

COLOMBIA
🏢

Address

CL 18 44 A-20, , Bogata, , Colombia

High Risk

FDA Import Risk Assessment

64.3
LowModerateHighCritical

This firm has a significant history of FDA import refusals with notable violations.

Statistics

12
Total Refusals
1
Unique Violations
4/10/2025
Latest Refusal
4/20/2018
Earliest Refusal

Score Breakdown

Violation Severity
90.0×40%
Refusal Volume
41.3×30%
Recency
70.8×20%
Frequency
17.2×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

7512×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

Refusal History

DateProductViolationsDivision
4/10/2025
65RDL12POTASSIC SALINE (INJECTION) (REPLENISHER)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/10/2025
56IDA76AZITHROMYCIN (MACAROLIDES)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/10/2025
60LDA01ACETAMINOPHEN (ANALGESIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/10/2025
56JDJ99LINCOMYCIN N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/10/2025
61WDA45FLUCONAZOLE (ANTI-FUNGAL) (NOT ANTIBIOTIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/5/2022
62YCY07MELOXICAM (ANTI-INFLAMMATORY, PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/2/2021
62OCE14AMLODIPINE BESYLATE (ANTI-HYPERTENSIVE, PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
1/21/2020
62OCY14AMLODIPINE BESYLATE (ANTI-HYPERTENSIVE, PART II)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/20/2018
60LDE69TRAMADOL HCL (ANALGESIC)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/20/2018
62GDA99ANTI-INFLAMMATORY N.E.C.
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/20/2018
56JDE20CLINDAMYCIN HYDROCHLORIDE HYDRATE (LINCOMYCINS)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/20/2018
56DDE06AMIKACIN SULFATE (AMINOGLYCOSIDES)
75UNAPPROVED
Division of Southeast Imports (DSEI)

Frequently Asked Questions

What is GENFAR SANOFI's FDA import refusal history?

GENFAR SANOFI (FEI: 3013021544) has 12 FDA import refusal record(s) in our database, spanning from 4/20/2018 to 4/10/2025.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. GENFAR SANOFI's FEI number is 3013021544.

What types of violations has GENFAR SANOFI received?

GENFAR SANOFI has been cited for 1 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about GENFAR SANOFI come from?

All FDA import refusal data for GENFAR SANOFI is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.